📊 Full opportunity report: GLP-1 Pharmacy Index on IdeaNavigator AI — validation score, market gap, and execution plan.
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
TL;DR
IdeaNavigator AI has outlined a proposed GLP-1 pharmacy index that would help patients compare dose availability and cash prices by ZIP code, while licensing the data to healthcare and benefits buyers. The concept is a proposed product, not a launched service; its accuracy, buyer demand and coverage remain unproven.
IdeaNavigator AI has proposed a GLP-1 pharmacy index that would show consumers where specific doses of four brand-name drugs are reported in stock and compare cash prices by ZIP code, while selling the normalized data to healthcare and benefits organizations. The concept addresses fragmented pricing and local supply information, but it is a product proposal, not a live index, and no pilot or customer commitments are confirmed, according to the proposal published by IdeaNavigator AI.
According to IdeaNavigator AI’s proposal, the consumer tool would cover Ozempic, Wegovy, Zepbound and Mounjaro. Patients would search by drug, dose and ZIP code for reported availability and the lowest listed legitimate cash price. The proposal says initial data would combine crowdsourced stock reports with publicly available prices from manufacturer direct channels, Costco, Walmart and a discount-price layer similar to GoodRx. It also proposes alerts when a requested dose becomes available.
For revenue, IdeaNavigator AI proposes keeping the consumer finder free and licensing an availability and price feed or dashboard to telehealth prescribers, employers and benefits brokers, and pharmacy benefit managers. The proposal suggests beginning with one or two business design partners. It also mentions possible referral fees from legitimate pharmacy or manufacturer-direct channels and says it would not use clinical affiliations with the drugs themselves.
The proposal recommends a 60-day validation test in one US metro area, with targets of at least 200 consumer stock reports and at least two business prospects signing a paid pilot or letter of intent. These are proposed benchmarks, not achieved results. The proposal identifies no metro, launch date, pilot partners or collected reports.
Price Gaps Reach Patients and Employers
IdeaNavigator AI says a searchable index could help patients paying cash compare prices and check whether a particular dose has been reported available nearby. Its proposal cites monthly cash prices ranging from roughly $199 to more than $1,000, depending on channel and product. It gives no date, drug-by-drug comparison or consistent price methodology for that approximate range.
The business case in the proposal rests on the view that information is scattered across pharmacies and direct-sales programs. IdeaNavigator AI says employers report GLP-1 medicines account for roughly 20% of pharmacy spend, but provides no survey, employer sample or measurement period to support that figure. If buyers need better visibility into prices and dose supply, a normalized feed might help them compare channels or plan benefits. Whether the data would be reliable and valuable enough to pay for has yet to be demonstrated.
From Shortages to Fragmented Supply
IdeaNavigator AI’s proposal describes a shift from broad shortage concerns toward more localized gaps in specific doses and wide variation in cash prices. It says the FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. The proposal links those changes, deadlines affecting compounded versions, and new manufacturer and retailer cash-pay channels to a more fragmented market. It provides no FDA citations or details about the scope and timing of the compounding deadlines.
The proposal also points to LillyDirect and NovoCare, along with Costco and Walmart programs, as channels whose prices a comparison tool could track. It mentions the TrumpRx portal in February 2026 as part of the expanding landscape. These are market-context claims in the proposal; it includes no portal-specific prices or availability figures. The proposed index would organize information across these channels rather than make treatment recommendations.
Coverage and Accuracy Remain Open
IdeaNavigator AI’s proposal does not show an operating index or establish whether pharmacies or manufacturers would provide a dependable feed. Crowdsourced reports could become outdated as stock changes, while listed prices may depend on eligibility, location, insurance status, coupons or other terms. The proposal does not explain how reports would be verified or timestamped, how the lowest legitimate price would be defined, or how conflicting information would be resolved.
The proposal also leaves unclear whether its cited price range applies to the same drug and dose, what the roughly 20% pharmacy-spend figure measures, and how widely shortages of particular doses persist. It names no business buyer and offers no evidence that patients would submit enough reports to keep local listings useful.
A 60-Day Market Test
IdeaNavigator AI’s proposal describes a possible single-metro test of a crowdsourced stock and cash-price tracker for the four named brands, paired with separate landing pages for consumers and prospective business buyers. The proposed 60-day test would measure whether it reaches 200 stock reports and secures two paid pilots or letters of intent. The proposal gives no launch schedule, and no results have been announced.
If the test proceeds, its results could indicate whether the consumer search tool attracts contributions and whether telehealth or employer-benefits teams will pay for the feed. Until a pilot is documented, the index’s coverage, price accuracy and commercial demand remain unresolved.
Key Questions
Is the GLP-1 pharmacy index available now?
No launch is confirmed. IdeaNavigator AI has described a proposed product and a possible 60-day validation test.
Which medicines would it cover?
The initial concept names Ozempic, Wegovy, Zepbound and Mounjaro, with searches organized by drug, dose and ZIP code.
Would patients have to pay to use the finder?
The proposal describes a free consumer tool. It would seek revenue by licensing price and availability data to business buyers, with possible referral fees from legitimate channels.
How would the proposal be tested?
It sets proposed 60-day targets of at least 200 consumer stock reports in one metro and two business prospects signing a paid pilot or letter of intent. No test results are reported.
How current would the stock and price listings be?
That has not been specified. The proposal does not explain verification, update frequency or how it would account for changing stock and price terms.
Source: IdeaNavigator AI
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
